Playbook › Playbook
A commercial-launch biotech's prior-year revenue is licensing, so YoY revenue growth prints negative during a successful launch
Claim
A newly commercial biotech has two revenue streams that behave nothing alike:
- Product revenue — sales of the drug. Compounds, carries normal COGS, is the thing you are trying to measure.
- Collaboration / licensing revenue — upfronts and milestones from partnering ex-US rights. Lumpy, recognised in bursts, and effectively 100% gross margin because there is no cost of goods against a signature.
In the first two or three years of a launch, stream 2 is frequently larger than stream 1. The year after a big upfront, total revenue falls. A screen reading total revenue concludes the company is shrinking at the exact moment the product is taking off.
The case that caught it — SPRY, 2026-08-20
| Fiscal year | Total revenue | Gross margin | Net income |
|---|---|---|---|
| FY2023 | $0.03M | — | −$54.37M |
| FY2024 | $89.15M | 99% | +$8.00M |
| FY2025 | $84.28M | 75.8% | −$171.30M |
FY2024 looks like the best year in company history — revenue near $90M, profitable. It was the ALK-Abelló collaboration upfront. neffy had been approved in August 2024 and had barely launched.
The tells were all in the same row:
- 99% gross margin. No epinephrine device business produces that. A drug-device combination runs 50–70%. A 99% margin means no product moved.
- Positive net income for a company that had never earned one before and has not since.
- The following year's margin collapsed to 75.8% — not deterioration, just mix shifting toward actual product.
Splitting the streams from the 10-Q inverts the picture entirely:
| Line | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|
| Product revenue, net | $12.80M | $17.45M | $26.21M |
| Collaboration revenue | $2.59M | $2.49M | $0.06M |
| Supply agreement revenue | $0.32M | $2.74M | $7.39M |
Product revenue: +105% YoY and +50% sequential. Total revenue on an annual basis: −5%.
The vendor layer makes it worse
Yahoo simultaneously published, for the same company on the same day:
RevGrowth(yoy)+1.14 (i.e. +114%) — a TTM figure, mostly product- an annual revenue series showing $89.15M → $84.28M, a 5% decline
Both are correct. They answer different questions over different windows, and neither is labelled. A reader taking either one alone is misled in opposite directions.
How to apply
- Never compute revenue growth for a launch-stage biotech from the total revenue line. Open the 10-Q income statement and take product revenue, net as its own series. It is almost always broken out separately, because the accounting requires it.
- Treat a gross margin above ~90% on a company that sells a physical product as proof the revenue is not product revenue. This is the fastest single tell and it needs no filings.
- Treat an isolated profitable year in a pre-profit biotech the same way. An upfront is the usual cause. Check whether the year before and after are both heavy losses.
- Watch the margin trajectory downward as a good sign during a launch. Falling blended gross margin means the mix is shifting from signatures to sales. Reading it as deterioration is the same error in another field.
- Supply-agreement revenue is a third category — real, recurring, tied to partner volumes, but at low margin and not a measure of the company's own commercial execution. SPRY's went $0.32M → $7.39M in a year and belongs in neither bucket cleanly.
Why it matters beyond arithmetic
The gap is also information about the business model. A company whose early revenue is mostly licensing has sold its international economics to fund a domestic launch. That is a real, permanent reduction in the terminal value which the revenue line never shows — and the same upfront that flatters year one is the reason years five through fifteen are smaller. On SPRY the ALK deal additionally generated a $74.9M financing liability that sits in the capital structure as debt-like and is counted in enterprise value.
What would falsify this
Nothing about the accounting — ASC 606 requires the disaggregation that makes the fix possible. The trap stops firing on any given company once licensing revenue becomes immaterial relative to product sales, typically three to four years into a launch.
Related
- [[pitfall-drug-sales-gross-vs-net-basis]] — same family, same sector: two true revenue figures for one drug on different bases.
- [[pitfall-growth-ratio-against-collapsing-base]] — the general form, where the denominator rather than the numerator does the lying.
- [[pitfall-divested-segment-corrupts-multiyear-cagr]] — a discontinuity in the revenue series that a CAGR silently absorbs.
- [[principle-primary-source-beats-vendor]] — the split is in the 10-Q and nowhere else.
History
- 2026-08-20 — found during
/analyze-smallcap SPRY. The 99% FY2024 gross margin was the tell; the ALK collaboration upfront was the cause. Caught before it reached a verdict, but only because the margin looked impossible for a device business.static— the mechanism is structural to launch-stage pharmaceutical accounting.